Acurx Pharmaceuticals, Inc.
ACXPNext catalyst
Ibezapolstat
Clostridium Difficile Infection
Get an email about ACXP's next catalysts
Track Acurx Pharmaceuticals (ACXP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ACXP Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.45 | FQ end Sep/2026 | Call: tbd
Ibezapolstat Phase 2 Est. Readout
Estimated primary completion for Ibezapolstat trial (NCT07513285) in Clostridium Difficile Infection Recurrence. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ibezapolstat | Phase 2 | Clostridium Difficile Infection | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Acurx Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Acurx Pharmaceuticals, Inc.'s (ACXP) pipeline across Phase 2. Its lead program is Ibezapolstat (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acurx Pharmaceuticals, Inc.'s next FDA catalyst?→
Acurx Pharmaceuticals, Inc.'s (ACXP) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACXP biotech catalysts?→
Add ACXP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acurx Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.